Medical Daily Article: Scaling Success: BiomeBank’s Product Offerings Unlock the Potential of Microbiome Therapy
Scaling Success - BiomeBank gets a write up in the Medical Daily.
Scaling Success - BiomeBank gets a write up in the Medical Daily.
LA weekly covers BiomeBank in this article.
Media Release: Australian biotech company BiomeBank has successfully secured a multimillion-dollar Federal Government grant that will turbo charge the development and production of microbiome-based therapies.
BiomeBank today announced the opening of its new GMP manufacturing facility designed to increase global supply of its approved donor derived microbiome-based therapy and further develop its second-generation therapies.
BiomeBank has announced the appointment of Kolby Day to the new position of Chief Operating Officer at the biotech drug development company based in Adelaide, South Australia.
Formal Therapeutic Goods Administration (“TGA”) approval of BiomeBank’s first-generation donor derived microbiome-based therapy.
The translation of research into the development of innovative and life-saving microbial therapies is set to transform in Australia through a partnership between Hudson Institute of Medical Research and BiomeBank, a clinical stage microbiome therapeutics company.
BiomeBank appoints Mr Chris Hall as Chair, effective 17 January 2022. Mr Hall brings over 30 years’ experience and impressive track record of investment management across both public and private markets within APAC. BiomeBank’s Series A funding round anticipated to close in early 2022. Formal Therapeutic Goods Association (“TGA”) approval of…
Super poo: the emerging science of stool transplants and designer gut bacteria As more people turn to faecal transplants for their health benefits, researchers in Adelaide are harnessing the power of high-quality poo in new treatments that can simply be swallowed